A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Shen, Binghui, Ph.D.

Laboratory of Binghui Shen, Ph.D.
The Shen laboratory has carried out various major National Institutes of Health-funded projects. In addition, we collaborate with Dr. Yuejin Hua of Zhejiang University, China, in the study of radiation-induced DNA damage responses in Deinococcus radiodurans.
 
Research Environment
The laboratory is located in the Beckman Research Institute at City of Hope in Duarte, California. Duarte is in the northeast suburbs of Los Angeles, just outside Pasadena, nestled in the foothills of the San Gabriel mountains. We're close to all of the entertainment and scenic attractions Southern California has to offer, yet far enough removed from the big city buzz. Take a half hour drive to the beach, or an hour and a half to local skiing. The medical center and Beckman Research Institute are situated on a beautiful, 112-acre campus, and our lab is housed in the Kaplan-Black Research Building.
 
Approximately 25 NCI-supported core facilities are available for biomedical research in City of Hope as a Comprehensive Cancer Center research facility. These include: microarray, mass-spectroscopy/protein sequencing, DNA sequencing, oligonucleotide & peptide synthesis, phosphor- and fluoro-imaging, histology/histochemistry, frozen tumor bank, time-lapse videography, confocal and electron microscopies, cytogenetics, NMR, flow-cytometry, molecular modeling, transgenic mice, and animal care.
 
An active Postdoctoral Association (PDA) promotes interaction between the Institute and postdoctoral fellows and graduate students, to help to ensure that their transition is smooth and their time here is as fulfilling as possible
 

Research

DNA Replication, Repair, and Apoptosis Nucleases in Genome Stability and Cancer
DNA replication and repair are critical for maintaining genome stability. These processes are in part dependent on the activities of an emerging family of structure-specific nucleases. Flap EndoNuclease 1 (FEN1) is a metallo- and substrate structure specific- nuclease. It possesses three distinct biochemical activities, functioning as a flap endonuclease (FEN), a nick-specific exonuclease (EXO), and a gapdependent endonuclease (GEN). FEN1 plays a critical role in maintaining human genome stability via six different pathways. It serves as a major nuclease for RNA primer removal during Okazaki fragment maturation and for long patch base excision repair using its FEN activity. Its concerted action of EXO and GEN activities is critical in resolution of di- and tri- nucleotide repeat secondary structures and stalled DNA replication forks, as well as in apoptotic cell DNA fragmentation. It also plays a major role in maintenance of telomere stability.
 
The multiple functions of FEN1 are regulated via three major mechanisms: formation of complexes with different protein partners, cellular compartmentation, and post-translational modifications. More than 30 proteins have been identified to interact with FEN1, forming specific complexes in different pathways. Upon acetylation, FEN1 translocates into the nucleus in response to DNA damage and cell cycle phase changes. It is very much enhanced in the nucleolus for maintenance of stability of tandem repeats of ribosomal DNA. FEN1 is also in mitochondrion, playing an important role in mitochondrial DNA replication and repair. The nuclease is acetylated, phosphorylated or methylated in different molecular events and the interaction between methylation and phosphorylation determines its recruitment onto DNA replication forks via proliferating cell nuclear antigen. The first group of FEN1 somatic mutations has been identified in human cancer cells, which has clear segregation of biochemical activities. The future emphasis will be placed on the mutations and prevalent polymorphisms that may impair one of the three major regulatory mechanisms. See Project 1  - Functional Analysis of FEN-1 Nuclease in Genome Stability.
 
Recently, we found that another major nuclease, DNA2, is dominantly localized into mitochondria and cooperatively processes replication and repair DNA intermediates for ligation and completion of circular mtDNA replication and repair. These novel and exciting observations prompted us to: i) knock out the DNA2 gene in mice to determine if defective DNA2-mediated RNA primer removal causes mitochondrial genomic instabilities, consequently promoting cancers and other genetic diseases, and ii) link functional defects of the DNA2 mutations identified in human mitochondrion-based diseases to pathologic mechanisms. Information made available from these studies should establish a relationship among the functions of these novel mitochondrial genes, unique mitochondrial mutagenic phenotype(s), and pathological mechanisms. The proposed study may also establish a foundation for the development of new treatment regimens for patients with mitochondrion-based cancers and other disorders. See Project 2 - Role of Nucleases in RNA Primer Removal and Mutagenesis.
 
The other novel nuclease that we are interested in is called TatD, which possesses a nick and 3’ exonuclease activity and is involved in apoptosis DNA fragmentation. In collaboration with Dr. John Williams in the Department of Molecular Medicine, we are currently undertaking a detailed 3-D structural and functional analysis of TatD to determine its role in apoptosis and the biological consequences, in human cells, of defects in this nuclease.
 

Project 1

Functional analysis of FEN1 nuclease in genome stability
The project was funded by NCI to test a hypothesis that subtle deficiency or defects in the individual biochemical activities of FEN1 may lead to different phenotypes in yeast and different susceptibilities in the human population to environmental stresses and individual differences in the onset of genetic diseases.
 
Figure to the right: E160D FEN1 mice are highly susceptible to cancers as a result of their mutator phenotype and chronic inflammation. The panel shows the chronic inflammation and Tumorigenesis in the lung. Top, disease incidence at specific life stages (timeline in months) of wild-type (WT), Fen1ED/+ (ED/+) and Fen1ED/ED (ED/ED) mice. Below, histology (H&E) of normal lung, lung with chronic inflammation, adenoma and adenocarcinoma in ED/ED mice. From: Zheng et al., 2008 Nature Medicine.
 

Project 2

Role of nuclease in RNA primer removal and mutagenesis
The major goals of this project are to carry out experiments to test roles of several eukaryotic nuclease complexes in RNA primer removal during lagging strand DNA synthesis in nuclei and mitochondria, and to examine the mutagenic consequences of defects of the individual nuclease complexes.
 
Localization of hDNA2 and mitochondria-lspecific heat-shock protein 70 (mtHSP70) in HeLa cells. hDNA2 (red) and mtHSP70 (green) were stained with antibodies to hDNA2 and mtHSP70. The nucleus (blue) was stained with DAPI. Yellow spots (arrows) indicate co-localization of hDNA2 and mtHSP70 (merged views). The square box in the upper right panel is a magnification of the area framed in white.
 

Lab Members

Huifang Dai, B.S.
Sr. Research Associate
Ph 626-256-HOPE (4673), ext. 63818
Fax 626-301-8892
hdai@coh.org
 
Joonas Jamsen, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. (W/A)
Fax 626-301-8892
jjamsen@coh.org
 
Weiqiang Lin, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext.64146
Fax 626-301-8892
wlin@coh.org
 
Guojun Lin, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 63818
Fax 626-301-8892
glu@coh.org
 
David Onyango, Ph.D.
Postdoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 65284
Fax 626-301-8892
donyango@coh.org
 
Julie Kanjanapangka
Graduate Student
Ph 626-256-HOPE (4673), ext. 62935
Fax 626-301-8892
jkanjanapangka@coh.org
 
Zhenxing Wu, M.S.
Predoctoral Fellow
Ph. 626-256-HOPE (4673), ext. 63518
Fax 626-301-8892
zhwu@coh.org
 
Li Zheng, Ph.D.
Assistant Research Professor
Ph 626-256-HOPE (4673), ext. 64147
Fax 626-301-8892
lzheng@coh.org
 
Mian Zhou, Ph.D.
Staff Scientist
Ph 626-256-HOPE (4673), ext. 64147
Fax 626-301-8892
mzhou@coh.org
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • A common surgical device, often used for minimally invasive hysterectomies, may be riskier than previously thought because of its potential to spread several types of cancer, not just uterine cancer, a new study has found. One out of every 368 women treated with a power morcellator – a device that cuts the uter...
  • Skin cancer rates have been on the rise for years. On Tuesday, the U.S. surgeon general said: Enough. In issuing the first-ever Call to Action to Prevent Skin Cancer, acting Surgeon General Boris Lushniak described skin cancer as a “major public health problem” that requires action by all segments o...
  • Learn more about becoming a patient or getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help you determine, before you come in, whether or not your insurance will pay for the ...
  • Counter-intuitive though it might seem, a prostate cancer diagnosis shouldn’t always lead to immediate prostate cancer treatment. Although prostate cancer is the second-leading cancer killer of men, behind lung cancer, and causes more than 29,000 deaths in the U.S. each year, in many cases, the tumors are...
  • Radiology is one of the cornerstones of any hospital. It is a key diagnostic branch of medicine essential for the initial diagnosis of many diseases and has an important role in monitoring a patient’s treatment and predicting outcome. Radiology is the specialty considered to be both the “eyes” and “ears” of med...
  • Donating blood and platelets saves lives. We all know this. Yet every summer, potential blood donors become distracted by vacations and schedule changes. As a result, blood donations fall dramatically across the nation, leaving hospitals frantically trying to bring in much-needed blood for their patients. Earli...
  • To be a great cancer hospital, you need a great oncology program. Just ask City of Hope – and Becker’s Hospital Review. The health care publishing industry stalwart, described as the “leading hospital magazine for hospital business news and analysis for hospital and health system executives,” recently selected ...
  • Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year. With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Ag...
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...